An Historic Perspective of Proteasome InhibitionESSELTINE, Dixie-Lee; MULLIGAN, George.Seminars in hematology. 2012, Vol 49, Num 3, pp 196-206, issn 0037-1963, 11 p.Article

Discovery and Development of Second-Generation Proteasome InhibitorsKIRK, Christopher J.Seminars in hematology. 2012, Vol 49, Num 3, pp 207-214, issn 0037-1963, 8 p.Article

Role of Intracellular Calcium in Proteasome Inhibitor-Induced Endoplasmic Reticulum Stress, Autophagy, and Cell Death : Disease, Drug Metabolism, and Transporter InteractionsWILLIAMS, Jessica A; YIFENG HOU; NI, Hong-Min et al.Pharmaceutical research. 2013, Vol 30, Num 9, pp 2279-2289, issn 0724-8741, 11 p.Article

Protective Immunity Remains Intact After Antibody Removal by Means of Proteasome InhibitionEVERLY, Matthew J; TERASAKI, Paul I; HOPFIELD, Judy et al.Transplantation. 2010, Vol 90, Num 12, pp 1493-1498, issn 0041-1337, 6 p.Conference Paper

Proteasome Inhibitors as Immunosuppressants: Biological Rationale and Clinical ExperienceMORAN, Eva; CARBONE, Federico; AUGUSTI, Valeria et al.Seminars in hematology. 2012, Vol 49, Num 3, pp 270-276, issn 0037-1963, 7 p.Article

Modulation of retroviral restriction and proteasome inhibitor-resistant turnover by changes in the TRIM5α B-box 2 domainDIAZ-GRIFFERO, Felipe; KAR, Alak; PERRON, Michel et al.Journal of virology. 2007, Vol 81, Num 19, pp 10362-10378, issn 0022-538X, 17 p.Article

Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132CRAWFORD, Lisa J. A; WALKER, Brian; OVAA, Huib et al.Cancer research (Baltimore). 2006, Vol 66, Num 12, pp 6379-6386, issn 0008-5472, 8 p.Article

Durability of Antibody Removal Following Proteasome Inhibitor-Based TherapyEVERLY, Matthew J; TERASAKI, Paul I; TRIVEDI, Hargovind L et al.Transplantation. 2012, Vol 93, Num 6, pp 572-577, issn 0041-1337, 6 p.Article

The Impact of Proteasome Inhibition on Alloantibody-Producing Plasma Cells In VivoDIWAN, Tayyab S; RAGHAVAIAH, Suresh; BURNS, Justin M et al.Transplantation. 2011, Vol 91, Num 5, pp 536-541, issn 0041-1337, 6 p.Article

Proteasome Inhibitors in Cancer Therapy : Lessons from the First Decade : The development of new cytotoxic agents in clinical oncologyORLOWSKI, Robert Z; KUHN, Deborah J.Clinical cancer research. 2008, Vol 14, Num 6, pp 1649-1657, issn 1078-0432, 9 p.Article

Histone deacetylase inhibitors in the treatment for multiple myeloma : PIH: Basic and Clinical Updates in Multiple MyelomaHIDESHIMA, Teru; ANDERSON, Kenneth C.International journal of hematology. 2013, Vol 97, Num 3, pp 324-332, issn 0925-5710, 9 p.Article

New Insights into the Treatment of Multiple Myeloma with Histone Deacetylase InhibitorsCEA, Michele; CAGNETTA, Antonia; GOBBI, Marco et al.Current pharmaceutical design (Print). 2013, Vol 19, Num 4, pp 734-744, issn 1381-6128, 11 p.Article

Primary ovarian cancer cells are sensitive to the proaptotic effects of proteasome inhibitorsPASQUINI, Luca; PETRONELLI, Alessia; PETRUCCI, Eleonora et al.International journal of oncology. 2010, Vol 36, Num 3, pp 707-713, issn 1019-6439, 7 p.Article

Hsp72 controls bortezomib-induced HepG2 cell death via interaction with pro-apoptotic factorsCALVARUSO, Giuseppe; GIULIANO, Michela; PORTANOVA, Patrizia et al.Oncology reports. 2007, Vol 18, Num 2, pp 447-450, issn 1021-335X, 4 p.Article

Proteasome inhibitors : antitumor effects and beyondNENCIONI, A; GRÜNEBACH, F; PATRONE, F et al.Leukemia. 2007, Vol 21, Num 1, pp 30-36, issn 0887-6924, 7 p.Article

Dissecting Bortezomib: Development, Application, Adverse Effects and Future Direction : Targeting the Ubiquitin-Proteasome Pathway - Current Perspectives and Future DirectionsBIYIN CAO; JIE LI; XINLIANG MAO et al.Current pharmaceutical design (Print). 2013, Vol 19, Num 18, pp 3190-3200, issn 1381-6128, 11 p.Article

Shikonin extracted from medicinal Chinese herbs exerts anti-inflammatory effect via proteasome inhibitionLI LU; AIPING QIN; XUEJUN WANG et al.European journal of pharmacology. 2011, Vol 658, Num 2-3, pp 242-247, issn 0014-2999, 6 p.Article

Characterization of the ubiquitin―proteasome system in bortezomib-adapted cellsRÜCKRICH, T; KRAUS, M; GOGEL, J et al.Leukemia. 2009, Vol 23, Num 6, pp 1098-1105, issn 0887-6924, 8 p.Article

Perturbation of DNA repair pathways by proteasome inhibitors corresponds to enhanced chemosensitivity of cells to DNA damage-inducing agentsTAKESHITA, Takashi; WENWEN WU; KOIKE, Ayaka et al.Cancer chemotherapy and pharmacology. 2009, Vol 64, Num 5, pp 1039-1046, issn 0344-5704, 8 p.Article

Analysis of changes in the proteome of HL-60 promyeloid leukemia cells induced by the proteasome inhibitor PSICHOI, Mi-Ran; NAJAFI, Farhad; SAFA, Ahmad R et al.Biochemical pharmacology. 2008, Vol 75, Num 12, pp 2276-2288, issn 0006-2952, 13 p.Article

Lysine 419 targets human glucocorticoid receptor for proteasomal degradationWALLACE, Andrew D; CAO, Yan; CHANDRAMOULEESWARAN, Sindhu et al.Steroids. 2010, Vol 75, Num 12, pp 1016-1023, issn 0039-128X, 8 p.Article

Treatment of relapsed or refractory Waldenström's macroglobulinemia with bortezomibDIMOPOULOS, Meletios A; ANAGNOSTOPOULOS, Athanasios; KYRTSONIS, Maria Christina et al.Haematologica (Roma). 2005, Vol 90, Num 12, pp 1655-1658, issn 0390-6078, 4 p.Article

TP-110, a New Proteasome Inhibitor, Down-regulates IAPs in Human Multiple Myeloma CellsIIJIMA, Masatomi; MOMOSE, Isao; IKEDA, Daishiro et al.Anticancer research. 2009, Vol 29, Num 4, pp 977-985, issn 0250-7005, 9 p.Article

Inhibitors of the Immunoproteasome: Current Status and Future Directions : The Ubiquitin Proteasome System as a Source of Drugs Targets for Cancer TherapyMILLER, Zachary; LIN AO; KYUNG BO KIM et al.Current pharmaceutical design (Print). 2013, Vol 19, Num 22, pp 4140-4151, issn 1381-6128, 12 p.Article

Trypanocidal Activity of β-Lactone-y-Lactam Proteasome InhibitorsSTEVERDING, Dietmar; XIA WANG; POTTS, Barbara C. M et al.Planta medica. 2012, Vol 78, Num 2, pp 131-134, issn 0032-0943, 4 p.Article